Eris Lifesciences Limited Q1FY25 Revenue at INR 720Crore

Varahi Media.com Mumbai, August 2, 2024: Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced its earnings for the first quarterofFY25.

Consolidated Financial Highlights:

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said,“We have integrated the Biocon acquisitions well ahead of schedule and started realising significant synergies in our flagship Domestic Branded Formulations business, which accounts for 90% of our revenue.We expect to clock a growth of 25% plus in the Biocon business in FY25 with significant margin expansion. Our business model has evolved from “specialty” to a “specialty plus super-specialty” model with the addition of segments such as Insulins, Oncology, Critical Care and Nephrology. As a Top-20 company in the IPM, we are taking tangible initiatives to step up our game in the Biotechnology space as well.”

Q1FY25- Financial Highlights

• Revenue of Q1 FY 25 grew by 54% YoY to INR 720Crore
• EBITDA for Q1 FY 25 is INR 250Crore, up 47% yoywith 35% EBITDA margin
• PAT for Q1 FY 25 is INR 89Crore with 12% PAT margin
• Net Debt as on 30June is INR 2,737Crore

Q1FY25 – Business Highlights

• Domestic Branded Formulations segment revenue grew by 39% yoy and EBITDA grew by 34%
• Eris now ranks among the Top-20 companies in the Indian Pharmaceutical Market (as per AWACS)
• Q1 growth for Eris is 12.7% vs. CVM growth of 8.1%: Eris isahead of market by 460 bps and has shown market-beating growth in 4 out of its top 6 therapies (as per AWACS)
• Eris ranks 3^rd in the IPM in terms of New Products Count and Value (as per AWACS)

About Author

varahimedia.com

See author's posts